Calcitonin gene-related peptide (CGRP) is a bioactive peptide produced by alternative splicing of the primary transcript of the calcitonin/CGRP gene. CGRP is largely distributed in the cardiovascular and nervous systems, where it acts as a regulatory factor. CGRP is also expressed in organs and tissues involved in metabolic regulation, including white adipose tissue (WAT), where its function is largely unknown. In this study, we examined the effects of endogenous CGRP on metabolic function. When we administered a high-fat diet to CGRP-specific knockout (CGRP 2/2 ) and wild-type (WT) mice for 10 weeks, we observed that food intake did not differ between the two groups, but body weight and visceral fat weight were significantly lower in CGRP 2/2 mice. Fatty liver changes were less severe in CGRP 2/2 mice, which also showed lower serum insulin and leptin levels. Glucose tolerance and insulin sensitivity were better in CGRP 2/2 than WT mice, and expired gas analysis revealed greater oxygen consumption by CGRP 2/2 mice. Adipocyte hypertrophy was suppressed in CGRP 2/2 mice, while expression of b-3-adrenergic receptor, hormone-sensitive lipase and adiponectin was enhanced. Isoproterenol-induced glycerol release from WAT was higher in CGRP 2/2 than WT mice, and CGRP 2/2 mice showed elevated sympathetic nervous activity. b-receptor-blockade canceled the beneficial effects of CGRP deletion on obesity. These results suggest that, in addition to its actions in the cardiovascular system, endogenous CGRP is a key regulator of metabolism and energy homeostasis in vivo. (Endocrinology 158: 1194(Endocrinology 158: -1206(Endocrinology 158: , 2017 
C alcitonin gene-related peptide (CGRP) is a 37-amino acid peptide produced by alternative splicing of the primary transcript of the calcitonin/CGRP gene (1) . CGRP is expressed primarily in motor and sensory neurons in both the central and peripheral nervous systems and has been shown to exert a variety of effects within the cardiovascular system (2), including vasodilation and positive inotropic effects on the heart (3). CGRP is also widely distributed in the digestive tract, lungs, kidney, liver, and adipose tissue (4, 5) , where it exerts various effects in addition to those affecting cardiovascular function (6) (7) (8) (9) . Associations between CGRP and human diseases, including hypertension (10), Raynaud's disease (11) , coronary (12) and cerebral artery spasm (13) , and migraine (14) , have also been reported.
To investigate the pathophysiological actions of endogenous CGRP, we generated CGRP-specific knockout (CGRP 2/2 ) mice using a targeting DNA construct that replaced exon 5, which encodes a CGRP-specific region of the gene (15) . In these mice, only CGRP is deleted; levels of calcitonin expression remain normal. At a glance, CGRP 2/2 mice develop normally, with no obvious growth retardation or body mass change. However, closer observation reveals that blood pressure, heart rate and sympathetic nervous system activity are all higher in CGRP 2/2 than wild-type (WT) mice (15) . CGRP 2/2 mice also show more severe damage in organ injury models, as CGRP modulates cytokine expression and prevents endothelial cell apoptosis (16) and fibrosis (17) . More recently, we reported that endogenous CGRP protects against neointimal hyperplasia in a vascular injury model by suppressing vascular smooth muscle proliferation (18) . These data clearly show that endogenous CGRP is an important mediator of organ homeostasis within the cardiovascular and nervous systems. Based on its structural homology and similar vasodilatory effects, CGRP has been classified as an adrenomedullin (AM) family peptide. We and others recently reported that, in addition to its cardiovascular effects, AM is an important regulator of metabolism (19, 20) , and CGRP appears to similarly contribute to metabolic regulation. For example, CGRP is reportedly involved in regulating glucose metabolism (21) , insulin sensitivity (22) , and appetite (23) . Interestingly, an earlier report showed that levels of CGRP are elevated in obese humans (24, 25) and animals (26) , and it was suggested that CGRP may contribute to metabolic diseases as it does to cardiovascular diseases. However, the pathophysiological importance of CGRP to metabolic disease remains unclear. In the current study, therefore, we investigated the function of endogenous CGRP in the metabolic system by chronically challenging WT and CGRP 2/2 mice with a high-fat diet and analyzing the phenotypes that emerge.
Materials and Methods

Animals
CGRP and calcitonin are encoded by the same gene. To avoid the effects of calcitonin deficiency, we generated CGRP 2/2 mice using a targeting DNA construct that replaced exon 5 of the gene, which encodes a CGRP-specific region (15) . C57BL/6 pure-background male mice were used. The mice were maintained under specific pathogen-free conditions in an environmentally controlled (12-hour light, 12-hour dark cycle; room temperature, 22 6 2°C) room. All experiments were performed at the Division of Laboratory Animal Research, Department of Life Science, Research Center for Human and Environmental Sciences, Shinshu University. All animal experiments were conducted in accordance with the ethical guidelines of Shinshu University.
Measurement of food intake
Mice were kept on either on a normal (4.7% energy as fat) or high-fat (32% energy as fat) diet (Clea Japan, Inc., Tokyo, Japan). To measure food intake, mice were housed separately in regular cages with a food intake measuring device (Shinfactory, Fukuoka, Japan). After allowing the mice to acclimate for at least 24 hours, food intake was measured over a period of 24 hours.
Expired gas analysis
Expired gas was analyzed using a Columbus Instruments Oxymax system (Columbus Instruments, Columbus, OH).
Mice were housed individually in plastic chambers with unlimited access to food and water. After allowing the mice to acclimate to the chambers for 48 hours, measurements were begun. Oxygen consumption (VO 2 ), carbon dioxide output (VCO 2 ), respiratory exchange ratio, and energy expenditure were recorded every 10 minutes for 48 hours under a 12-hour light/dark cycle at a room temperature of 22 6 2°C. RNA extraction and quantitative real-time reverse transcription polymerase chain reaction Total RNA was extracted from tissues using TRIZOL Reagent (Invitrogen, Carlsbad, CA), after which the sample was treated with DNA-Free (Ambion, Austin, TX) to remove contaminating DNA and subjected to reverse transcription using a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA). Quantitative real-time reverse transcription polymerase chain reaction (PCR) was carried out using an Applied Biosystems 7300 real-time PCR System (Applied Biosystems) with SYBR green (Toyobo, Osaka, Japan) or Realtime PCR Master Mix (Toyobo). Values were normalized to mouse GAPDH (predeveloped TaqMan assay reagents, Applied Biosystems). Primers are listed in Table 1 .
Glucose and insulin tolerance tests
For the oral glucose tolerance test (OGTT), mice were fasted for 16 hours and then fed 1 g/kg glucose (Wako, Tokyo, Japan). Blood glucose was measured 0, 15, 30, 60, and 120 minutes after the glucose load. Serum insulin concentrations were measured using an enzyme-linked immunosorbent assay kit (Shibayagei, Gunma, Japan). For the insulin tolerance test (ITT), mice were fasted for 2 hours, after which 1.5 U/kg human insulin (Humulin R, Eli Lilly Japan, Hyogo, Japan) was injected intraperitoneally. Blood glucose was then measured 0, 15, 30, 60, and 120 minutes after the injection.
Histology
White adipose tissue (WAT) and the liver were excised from each mouse, fixed in 4% paraformaldehyde for 24 hours and embedded in paraffin. The tissues were then cut into 5-mm sections, which were stained with hematoxylin-eosin and/or Masson trichrome. For F4/80 immunohistochemical analysis, sections were incubated with rat anti-mouse F4/80 antibody (Bio-Rad, Hercules, CA). The distribution of adipocyte sizes was evaluated using BIOREVO BZ-9000 BZ-H1 measurement software (KEYENCE, Osaka, Japan). Antibody is listed in Table 2 .
Urinary catecholamine levels
To determine the urinary levels of a norepinephrine metabolite, normetanephrine, mice were housed in individual metabolic cages. After 3 days, a small amount of 6 N HCl was added to the beaker placed in the cage, and the acidic urine was collected for the next 24 hours. Urinary normetanephrine concentrations were then measured by a subcontractor (SRL, Tokyo, Japan).
Open-field test
The apparatus consisted of an empty bright open-field arena surrounded by walls (45 3 45 3 40 cm). Twice each day, mice were individually placed in the center of the apparatus, which initiated a 10-minute test session. Mouse behavior was recorded and analyzed using a Spontaneous Motor Activity Recording and Tracking software system (SMART v. 3.0; Panlab, Barcelona, Spain).
Primary adipocyte lipolysis activity
Equal amounts of epididymal WAT from WT and CGRP 2/2 mice were incubated in Dulbecco's modified Eagle medium containing 2% fatty acid-free bovine serum albumin and 10 mm isoproterenol. The tissue was incubated for 3 hours at 37°C under a 5% CO 2 atmosphere, during which 10 ml of medium were extracted at 1-hour intervals. The collected samples were incubated for 5 minutes at 37°C after adding free glycerol reagent. The absorbance at 540 nm was then measured and compared with absorbances obtained with glycerol standard solutions.
Western blotting
Mice were fasted overnight and injected 1.25 U/kg insulin or saline via the tail vein. Five minutes after the injection, WAT was excised, lysed in ice-cold RIPA Lysis Buffer System (Santa Cruz Biotechnology, Dallas, TX) supplemented with PhosSTOP phosphatase inhibitor (Roche Applied Science, Penzberg, Germany) and then sonicated. The resultant lysates were subjected to ; Cell Signaling Technology, Danvers, MA). Anti-b-tubulin antibody (Santa Cruz Biotechnology) served as a loading control. The bound antibodies were visualized using chemiluminescent HRP substrate (Merck Millipore, Billerica, MA), and the chemiluminescence was analyzed using an Image Quant LAS 4000 system (GE Healthcare, Little Chalfont, UK). Antibodies are listed in Table 2 .
b-Blocker administration
Propranolol (AstraZeneca, London, UK), a nonselective b-adrenergic receptor antagonist, was dissolved in 0.5% methylcellulose. CGRP 2/2 mice on a high-fat diet were orally administered either propranolol (30 mg/kg/d) or control vehicle in their drinking water for 8 weeks, beginning when they were 8 weeks old. Body weights were measured weekly.
Statistical analysis
Values are expressed as means 6 standard error of the mean. Student's t test, two-way analysis of variance or x 2 test was used to determine significant differences. For the analysis of energy expenditure, we used analysis of covariance (27) . All analyses were performed using SPSS software (v. 18). Values of P , 0.05 were considered significant.
Results
CGRP
2/2 mice show resistance to weight gain without a change of appetite We initially explored changes in the body weights of WT and CGRP 2/2 mice on normal and high-fat diets.
The body weights of the mice were measured weekly for 10 weeks. When on a normal diet (4.7% energy as fat), the two groups exhibited similar weight gains from 8 to 18 weeks of age. CGRP 2/2 mice tended to have lower body weights than WT mice, but the difference was not significant [ Fig. 1(a) ]. On a high-fat diet (32% energy as fat), both WT and CGRP 2/2 mice had higher body weights than mice on a normal diet, but the weight gains were clearly smaller in CGRP 2/2 than WT mice
The difference in weight gain did not appear to reflect a difference in appetite or food intake, which were similar in WT and CGRP mice on a (a) normal diet (4.7% energy as fat) and (b) high-fat diet (32% energy as fat) from 8 to 18 weeks of age. n = 5 in both groups. Body weights were measured weekly and expressed as the mean 6 standard error of the mean. Statistical significance was analyzed using two-way analysis of variance. ***P , 0.001. Experiments were repeated four times, and similar results were obtained each time. Fig. 1 ).
Glucose metabolism was enhanced in CGRP 2/2 mice Because CGRP 2/2 mice resisted weight gain and showed changes in the expired gas, we next evaluated glucose and other metabolic parameters in WT and CGRP 2/2 mice after 10 weeks of a high-fat diet. CGRP 2/2 mice showed better tolerance to a glucose load. This was apparent at nearly all time points tested during OGTTs [ Fig. 4(a) ]. Combined with the results of ITTs [ Fig. 4(b) ], these data show that glucose metabolism was enhanced in CGRP 2/2 mice. On the other hand, the OGTT and ITT results were not significantly different between WT and CGRP 2/2 on normal diet (Supplemental Fig. 2) , suggesting that the enhanced glucose metabolism in CGRP 2/2 becomes apparent only under the high-fat diet. Consistent with their resistance to body weight gains, the serum concentrations of insulin and the adipocyte-derived hormone leptin were significantly lower in CGRP 2/2 than WT mice [ Fig. 4(c) and 4(d) ]. On the other hand, serum concentrations of triglyceride, free fatty acid, and total cholesterol were similar in the two groups [ Fig. 4(e) ]. These results demonstrate that glucose tolerance and insulin handling are enhanced in CGRP 2/2 mice on a high-fat diet, as compared with WT mice on the same diet.
Adipocyte hypertrophy and fatty liver changes were suppressed in CGRP 2/2 mice Consistent with their resistance to weight gain while on a high-fat diet, CGRP Upregulated expression of lipolysis-related genes in WAT from CGRP 2/2 mice on a high-fat diet To further examine the mechanism underlying the resistance to adipocyte hypertrophy and obesity in CGRP 2/2 mice, we used quantitative real-time PCR to assess gene expression in WAT from mice fed a high-fat diet for 10 weeks. We found that expression of genes associated with lipolysis, including hormone-sensitive lipase (HSL), comparative gene identification-58 (CGI-58), perilipin, and b-3-adrenergic receptor (b-3-AR), were all significantly upregulated in CGRP 2/2 mice. In particular, levels of b-3-AR expression were increased several-fold as compared with WT mice [ Fig. 6(a) ]. The expression of adiponectin . Expired gas analysis in WT and CGRP 2/2 mice on a (a-d) normal diet or (e-h) high-fat diet. Studies were performed under a 12-hour light and 12-hour dark cycle at a room temperature of 22 6 2°C. (a, e) VO 2 , (b, f) VCO 2 , (c, g) respiratory exchange ratio (RER), and (d, h) energy expenditure were compared between WT and CGRP 2/2 mice. Means of these parameters for all day and the light and dark portions of the day are shown. n = 5 in each group. All values are expressed as the mean 6 standard error of the mean. *P , 0.05; **P , 0.01; ***P , 0.001 vs WT. also significantly upregulated in WAT from mice fed a normal diet (Supplemental Fig. 3) .
The expressions of brown adipose tissue (BAT) markers in BAT and beigeing-associated genes in WAT were not different between WT and CGRP 2/2 (Supplemental Fig. 4 mice, which may explain the resistance to adipocyte hypertrophy and obesity.
Ability to release glycerol is preserved in CGRP 2/2 mice on a high-fat diet We next examined the ability of WAT from WT and CGRP 2/2 mice to release glycerol in vitro. Epididymal WAT was collected from mice and incubated in culture medium containing 10 mm isoproterenol. Glycerol released into the medium was then measured at 1-hour intervals for 3 hours. In WT mice, the ability to release glycerol was significantly reduced by a high-fat diet as compared with a normal diet (Fig. 7, left) . On the other hand, glycerol release was preserved in CGRP 2/2 mice, even on the high-fat diet (Fig. 7, right) .
Elevated sympathetic nerve activity and locomotor activity in CGRP 2/2 mice CGRP is known to contribute to the regulation of cardiovascular function through inhibitory modulation of sympathetic nervous activity (15) . To assess sympathetic nerve activity of WT and CGRP 2/2 mice, we measured urinary levels of normetanephrine a catecholamine metabolite, and found that normetanephrine excretion was significantly higher in CGRP 2/2 than WT mice [ Fig. 8(a) ]. This suggests that sympathetic nervous activity is augmented in CGRP 2/2 mice.
We assessed locomotor activity by placing mice in the center of an empty bright open field arena surrounded by walls. Recording their movement for 10 minutes revealed that CGRP 2/2 mice traveled significantly longer distance than WT mice [ Fig. 8(b) ]. Apparently, CGRP
2/2
mice are more active than WT mice. 2/2 mice were fed a high-fat diet for 10 weeks. n = 5 in each group. Expression levels in CGRP 2/2 were normalized to WT, which was assigned a value of 1. AdPLA2, adipose phospholipase A2; PPAR, peroxisome proliferator activated receptor; UCP, uncoupling protein. All values are expressed as the mean 6 standard error of the mean. Statistical significance was analyzed using unpaired Student's t test. *P , 0.05; ** P , 0.01 vs WT. (e) p-AMPK (upper panels) and p-HSL (lower panel) were analyzed in WAT from mice on a high-fat diet for 10 weeks. WAT was extracted and processed for western blot analysis. b-tubulin was used as a loading control. Blots are representative of three experiments. (f) Result of the densitometry analysis of the western blotting. Bars depict means 6 standard error of the mean.
We tested whether the body weight difference between WT and CGRP 2/2 mice could be canceled by suppressing the elevation in sympathetic nervous activity. When propranolol, a nonselective b-blocker, was administered during the high-fat diet, the body weight difference between WT and CGRP 2/2 mice disappeared [ Fig. 8(c) ].
The significant differences in VO 2 and VCO 2 on the high-fat diet were also canceled by the b-blocker (Supplemental Fig. 5 ). We also analyzed the gene expression in WAT from mice fed a high-fat diet with oral administration of the b-blocker and found that the difference between CGRP 2/2 and WT was canceled by the b-blocker (Supplemental Fig. 6 ).
Discussion
Our main findings in this study are that CGRP 2/2 mice are protected from highfat diet-induced obesity and display improved glucose handling and insulin sensitivity. CGRP 2/2 mice also showed elevated oxygen consumption and carbon dioxide output. Consistent with the resistance to weight gain, CGRP 2/2 mice had less fat mass and lower liver weights than WT mice, with less adipocyte hypertrophy and fatty liver changes than WT mice. In the WAT from CGRP 2/2 mice, expression of genes related to lipolysis and mitochondria was elevated, and glycerol release was preserved, even in mice on a high-fat diet.
In addition, sympathetic nerve activity and locomotor activity were both elevated in CGRP infiltration. Thus expression levels of genes associated with lipolysis and adipocyte differentiation as well as mitochondria-related genes were all significantly elevated in CGRP 2/2 WAT. In addition, HSL and AMPK, which promote lipolysis and energy dissipation in WAT (28) , were also more activated in CGRP 2/2 WAT.
CGRP is expressed in sensory C and Ad-fibers via activation of transient receptor potential vanilloid 1 (TRPV1) (29) . Interestingly, the phenotype of TRPV1 knockout mice (TRPV1 2/2 ) resembles that of CGRP 2/2 mice, in that TRPV1 2/2 mice are also protected from dietinduced obesity (30) . On an 11% fat diet, TRPV1 2/2 mice gained significantly less adiposity than WT mice, despite equivalent energy intake. The precise mechanism by which TRPV1 influences energy and lipid handling is unclear, but it has been suggested that TRPV1 contributes to the regulation of adipocyte function. TRPV1 triggers release of neuropeptides from sensory nerve terminals innervating fatty tissues (30) . This suggests the resistance to obesity and adiposity exhibited by TRPV1 2/2 mice could be, at least in part, explained by decreased release of CGRP. Our results differ from those of Danaher et al. (31) , who reported that exogenous administration of CGRP evoked lipolysis through elevation of fatty-acid b-oxidation and AMPK signaling both in vitro and in vivo. It may be that effects of exogenous CGRP administration do not reflect the physiological effects on metabolic processes revealed by manipulating endogenous CGRP. Carter et al. (23) reported that CGRP-expressing neurons in the outer external lateral subdivision of the parabrachial nucleus, which project to the laterocapsular division of the central nucleus of the amygdala, form a functionally important circuit for suppressing appetite. Lutz et al. (32) reported that intracerebroventricular injection of CGRP(8-37), a CGRP antagonist, increased food intake. These findings suggest CGRP exerts anorectic effects within the central nervous system. However, because CGRP is produced by various tissues other than central nervous system and functions as a circulating hormone as well as a neurotransmitter, the CGRP 2/2 mouse is a suitable model for evaluating the total effect of endogenous CGRP on foodintake. Walker et al. (5) reported that food intake was increased in CGRP 2/2 mice on a high-fat diet. In the current study, by contrast, we detected no difference of food-intake between CGRP 2/2 and WT mice, whether on a high-fat or normal diet. We also confirmed that there was no difference in hypothalamic levels of orexigenic or anorexigenic neuropeptides between the two groups. A key difference between the current study and that of Walker et al. (5) was the high-fat diet regimen. Those investigators observed increased food intake only by CGRP 2/2 mice on a 60% fat diet, whereas our high-fat diet contained 32% fat. In addition, they analyzed total food intake during a study period of 42 to 224 days, whereas we evaluated daily food intake for 10 weeks. Thus both the content and feeding period differed between the two studies, which could affect the phenotype of CGRP Although the metabolic functions of CGRP have been reported, its role in insulin sensitivity remains controversial, and previous studies ascribed both proand antidiabetic actions to CGRP (33) . In streptozotocininduced diabetic rats, for example, CGRP-immunoreactive nerves were markedly increased in the epidermis and dermis from an early stage, implicating altered in CGRP in the initial stages of diabetes (34). Leighton et al. (22) reported that CGRP is a potent inhibitor of both basal and insulin-stimulated rates of glycogen synthesis in skeletal muscle in vitro, whereas Molina et al. (35) reported that intravenous infusion of CGRP caused insulin resistance in vivo. On the other hand, Sun et al. (36) reported that intramuscular transfer of CGRP gene suppressed proinflammatory Th1 subsets and promoted anti-inflammatory Th2 subsets, which ameliorated b-cell destruction in streptozotocin-induced diabetes. In the current study, we found that CGRP deletion reduced hyperinsulinemia and improved glucose tolerance and insulin sensitivity in mice on a high-fat diet. These results suggest endogenous CGRP exerts negative metabolic effects in obesity.
The loss of CGRP's effect on sympathetic nerve activity may also contribute to the metabolic changes seen in CGRP 2/2 mice. We previously reported that CGRP 2/2 mice showed elevated blood pressures and heart rates, and suggested that CGRP acts to inhibit sympathetic effects on cardiovascular function (15) . In the current study, we observed that urinary normetanephrine excretion was increased in CGRP 2/2 mice, which also displayed hyperactivity in an open field test. These observations are consistent with the idea that sympathetic nervous activity is increased in CGRP 2/2 mice. It is thus noteworthy that propranolol, a b-blocker that inhibits sympathetic nerve activity, eliminated the difference in weight gain between WT and CGRP 2/2 mice on high-fat diet. The significant differences in VO 2 , VCO 2 , and the gene expression in WAT on the high-fat diet were also canceled by b-blocker. We therefore also suggest that CGRP contributes to the regulation of metabolism through inhibitory modulation of sympathetic nervous activity. At a glance, our results suggest CGRP blockade could be useful in the treatment of obesity; however, its varied effects in multiple organs and tissues may make its use complicated. Very recently, Nilsson et al. (37) reported that a long-acting (half-life . 10 hours) CGRP analog improved metabolic conditions in ob/ob mice and dietinduced obese rats. In the future, studies using conditional or inducible gene-edited mice may help further our understanding of the pathophysiological functions of CGRP in metabolic diseases and provide novel therapeutic approaches targeting this attractive molecule.
In summary, we found that CGRP 2/2 mice were protected from high-fat diet-induced obesity and displayed enhanced glucose metabolism. In CGRP 2/2 mice, adipocyte hypertrophy was suppressed by elevated lipolysis and sympathetic nervous activity. Our findings clearly show that endogenous CGRP is a key regulator of metabolism and could be a novel therapeutic target in metabolic and cardiovascular diseases.
